Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy.

@article{Edwards2018AssessmentOT,
  title={Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy.},
  author={Adam B Edwards and Ryan S. Anderton and Neville W. Knuckey and Bruno P Meloni},
  journal={Journal of neuroscience research},
  year={2018},
  volume={96 11},
  pages={
          1816-1826
        }
}
Hypoxic-ischaemic encephalopathy (HIE) remains the leading cause of mortality and morbidity in neonates, with no available neuroprotective therapeutic agent. In the development of a therapeutic for HIE, we examined the neuroprotective efficacy of the poly-arginine peptide R18D (arginine 18 mer synthesised with D-arginine) in a perinatal model of hypoxia-ischaemia (HI; common carotid and external carotid occlusion + 8%O2 /92%N2 for 2.5 hr) in the P7 Sprague-Dawley rat. R18D was administered… CONTINUE READING
BETA
3
Twitter Mentions